PEP503 (NBTXR3), a radioenhancer, in combination with concurrent chemoradiation (CCRT) in locally advanced or recurrent head and neck squamous cell carcinoma (HNSCC): Dose-finding of a phase 1b/2 trial.

被引：0

作者：

Wang, Cheng-Hsu

Chao, K. S. Clifford

Chen, Ping-Tsung

Yeh, Kun-Yun

Chen, Yen-Chao

Chen, Yao-Liang

Yang, Shih-Wei

Wu, Tsung-Han

Chang, Pei-Hung

Young, Chi-Kuang

Tsan, Din-Li

Tsai, Ming-Hsui

Hsieh, Ching-Yun

Chen, Wen-Cheng

Tsai, Yuan-Hsiung

Hsu, Cheng-Ming

Chang, John W. C.

Yu, Wei-Che

Shen, Bor-Nian

机构：

[1] Chang Gung Mem Hosp, Keelung, Taiwan

[2] Chang Gung Univ, Coll Med, Keelung, Taiwan

[3] China Med Univ Hosp, Canc Ctr, Taichung, Taiwan

[4] Chiayi Chang Gung Memoal Hosp, Putz, Chiayi, Taiwan

[5] Chang Gung Mem Hosp, Keelung, Taiwan

[6] Keelung Chang Gung Mem Hosp, Keelung, Taiwan

[7] Chang Gung Univ, Chang Gung Mem Hosp, Taoyuan City, Taiwan

[8] Chang Gung Mem Hosp, Dept Internal Med, Keelung, Taiwan

[9] China Med Univ Hosp, Taichung, Taiwan

[10] Chiayi Chang Gung Memor Hosp, Chiayi, Taiwan

[11] Chang Gung Med & Nursing Village, Kweshan Hsiang, Taiwan

[12] PharmaEngine Inc, Taipei, Taiwan

[13] PharmaEngine, Taipei, Taiwan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e18041

引用

页码：E18041 / E18041

页数：1

共 42 条

[31] NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator's choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma.
Le Tourneau, Christophe
Hoffmann, Caroline
Takacsi-Nagy, Zoltan
Liem, Xavier
Salas, Sebastien
Debard, Anais
Finzi, Laetitia
Farber, Leonard A.
Gogishvili, Miranda
Kristesashvili, Giorgi
Makharadze, Tamta
Yom, Sue S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
Oppelt, Peter John
Ley, Jessica C.
Paniello, Randal C.
Puram, Sidharth
Jackson, Ryan
Pipkorn, Patrik
Rich, Jason
Gay, Hiram Alberto
Liu, Jingxia
Cohen, Jared
Thorstad, Wade
Adkins, Douglas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC)
Cognetti, David M.
Curry, Joseph M.
Civantos, Francisco F.
Valentino, Joseph
Agbaje-Williams, Mayowa
Danesi, Hassan
Dong, Haiying
Larracas, Cristina
Veresh, Bogdan
Gillenwater, Ann M.
Su, Shirley Y.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] Preliminary Safety and Tolerability of a Phase 1 Trial of Olaparib in Combination With Cetuximab and Radiation Therapy in Heavy Smokers With Locally Advanced, Stage IVA-B Squamous Cell Carcinoma of the Head/Neck Molecular Biology and Therapeutics
Waxweiler, T.
Bowles, D.
Reddy, K.
Blatchford, P.
Song, J. I.
Leem, T.
Jimeno, A.
Raben, D.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 517 - 518
[35] Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.
Cohen, Jared
Ley, Jessica C.
Liu, Jingxia
Haselhorst, Emma
Oppelt, Peter John
Adkins, Douglas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).
Harrington, Kevin J.
Kong, Anthony Hee
Mach, Nicolas
Rordorf, Tamara
Jaime, Jesus Corral
Espeli, Vittoria
Treichel, Sheryl
Gumuscu, Burak
Kim, Jenny J.
Chesney, Jason Alan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.
Harrington, Kevin Joseph
Kong, Anthony
Mach, Nicolas
Chesney, Jason Alan
Castelo, Beatriz
Rischin, Danny
Cohen, Ezra E. W.
Radcliffe, Hoi-Shen
Gumuscu, Burak
Snyder, Wendy
Siu, Lillian L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[38] Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Nywening, Timothy M.
Wang-Gillam, Andrea
Sanford, Dominic E.
Belt, Brian A.
Panni, Roheena Z.
Cusworth, Brian M.
Toriola, Adetunji T.
Nieman, Rebecca K.
Worley, Lori A.
Yano, Motoyo
Fowler, Kathryn J.
Lockhart, A. Craig
Suresh, Rama
Tan, Benjamin R.
Lim, Kian-Huat
Fields, Ryan C.
Strasberg, Steven M.
Hawkins, William G.
DeNardo, David G.
Goedegebuure, S. Peter
Linehan, David C.
[J]. LANCET ONCOLOGY, 2016, 17 (05): : 651 - 662
[39] Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018; 19: 405-15
Di Nunno, Vincenzo
Santoni, Matteo
Massari, Francesco
[J]. EUROPEAN UROLOGY, 2018, 74 (02) : E50 - E50
[40] Early safety from phase 1b/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): MASTERKEY-232
Harrington, K.
Kong, A.
Mach, N.
Rordorf, T.
Corral, J.
Espeli, V.
Treichel, S.
Cheng, J.
Kim, J.
Chesney, J.
[J]. ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →